“We have one of the World’s Most Advanced Functional HIV Cures under development”

04/07/2016 - 5 minutes

Abivax has recently announced that it’s likely that its most advanced program in hepatitis B will fail its Phase III trials. That’s really bad news for the company, and stocks have plummeted by around 50%. But what does this really mean for the future of Abivax? To find out, I had a chat with the company’s CEO Hartmut Ehrlich and its CMO Jean-Marc Steens…

Abivax hiv hepatitis antiviral biotechAbivax is one of the high-profile Biotechs in Paris. With a pipeline with candidates for hepatitis B and HIV, it raised €57M during its IPO on the Euronext Paris – the biggest ever in French Biotech.

But its stock price is now suffering from the most recent news. Abivax has announced that its Phase III for hepatitis B is not having the best results, and it’s very unlikely that the primary endpoint will be met – essentially a Phase III failure.

ABX-203 is still Abivax’s most advanced candidate and was leading the race for a hepatitis B virus treatment.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT Do you want to remove this advert? Become a member!
ADVERTISEMENT Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member